EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac events
European regulators are poised to approve Novo Nordisk’s blockbuster drug Wegovy to reduce the risk of cardiovascular events in patients who are overweight or obese …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
